新規Midkine阻害剤iMDKの口腔扁平上皮癌に対する抗腫瘍効果と抗血管新生効果の検討 by Masui, Masanori
Abstract. Midkine is a heparin-binding growth factor highly
expressed in various human malignant tumors. However, its role
in the growth of oral squamous cell carcinoma is not well
understood. In this study, we analyzed the antitumor effect of a
novel midkine inhibitor (iMDK) against oral squamous cell
carcinoma. Administration of iMDK induced a robust antitumor
response and suppressed cluster of differentiation 31 (CD31)
expression in oral squamous cell carcinoma HSC-2 cells and
SAS cells xenograft models. iMDK inhibited the proliferation of
these cells dose-dependently, as well as the expression of midkine
and phospho-extracellular signal-regulated kinase in HSC-2 and
SAS cells. Moreover, iMDK significantly inhibited vascular
endothelial growth factor and induced tube growth of human
umbilical vein endothelial cells in a dose-dependent fashion.
These findings suggest that midkine is critically involved in oral
squamous cell carcinoma and iMDK can be effectively used for
the treatment of oral squamous cell carcinoma.
Although oral squamous cell carcinoma is one of the most
common types of human cancer, there has been little
improvement in patient morbidity in the past 50 years (1).
Despite advances in early detection, diagnosis, and
management of oral squamous cell carcinoma, long-term
survival rates have improved only marginally over the past
decade (2, 3). Therefore, novel therapeutic approaches for
oral squamous cell carcinoma are needed.
Midkine is a heparin-binding growth factor that is highly
expressed in many malignant tumors, including lung (4),
breast (5), esophageal (6), stomach (7), colon (8),
hepatocellular (9), and pancreatic (10) cancer, and oral
squamous cell carcinoma (11). Midkine has cancer-related
functions in tumor cell survival, mitogenesis, transformation,
anti-apoptosis, and cell growth (12). The expression of
midkine was previously found to be elevated in blood
samples from oral squamous cell carcinoma patients and was
associated with patient prognosis (13). Inhibition of midkine
by small-interfering RNA has been shown to suppress
growth of oral squamous cell carcinoma cells by controlling
expression of cell cycle-regulating genes (14), indicating that
midkine might be a potential target for oral squamous cell
carcinoma therapy. Synthetic peptides and compounds for
targeting midkine-mediated cell migration have been
identified; however, these inhibitors lack clinical approval
(15). A low-molecular-weight compound 3-[2-(4-
fluorobenzyl) imidazo [2,1-beta] thiazol-6-yl]-2H-chromen-
2-one (hereafter referred to as iMDK) that suppresses
endogenous midkine expression was identified. iMDK has
potent antiproliferative and antitumor effects in vitro and in
vivo in non-small-cell lung cancer (16).
In the present study, we analyzed the antitumor effect of
iMDK against progression of oral squamous cell carcinoma. 
Materials and Methods
Cell lines and culture conditions. Human oral squamous cell
carcinoma cell lines SAS and HSC-2 obtained from the Human
Science Research Resources Bank (Osaka, Japan) were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% heat-
inactivated fetal bovine serum. Human vascular endothelial cells
(HUVECs), newly obtained from the RIKEN BioResource Center
Cell Bank (Tsukuba, Japan) were cultured in EBM-2 supplemented
with 10% heat-inactivated fetal bovine serum. All of these cell lines
were characterized by genotyping at the cell banks. All cell lines
were cultured in an atmosphere of 10% CO2 at 37˚C.
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Agent. iMDK was purchased from ChemDiv (San Diego, CA, USA)
and dissolved in dimethyl sulfoxide (DMSO).
Histochemical and immunohistochemical analysis of surgically
resected samples. The study was approved by the Ethical Review
Committee of the Okayama University Graduate School of
Medicine and Dentistry, and Pharmaceutical Sciences (protocol
number: 1949). Hematoxylin-eosin-stained specimens were prepared
from surgically resected oral squamous cell carcinoma samples.
Sections from the deepest part of the tumor invasion were evaluated
primarily by light microscopic observation. All of the patients were
examined and treated at Okayama University Hospital (Okayama,
Japan) between 2000 and 2014, and the diagnoses were
clinicopathologically confirmed. No patient had received
chemotherapy or radiation therapy before surgery. All tumor
samples were obtained with the consent of the patients. The sections
were sequentially deparaffinized through a series of xylene, graded
ethanol, and water immersion steps. After being autoclaved in 0.2%
citrate buffer for 15 min, the sections were incubated with 3%
hydrogen peroxide for 30 min to block endogenous peroxidase
activity. A primary antibody to midkine (rabbit IgG) from Abcam
(Cambridge, MA, USA) was used for the immunohistochemical
analysis. The specimens were incubated with 1:200 dilution of the
antibody overnight at 4˚C, followed by three washes with tris-
buffered saline (TBS). The slides were then treated with a
streptavidin-biotin complex, EnVision horseradish peroxidase (HRP)
(Dako, Carpinteria, CA, USA) for 60 min at a dilution of 1:100. The
immunoreaction was visualized using a 3,3’-diaminobenzidine
(DAB) substrate-chromogen solution (Dako Cytomation Liquid
DAB Substrate Chromogen System; Dako), and counterstaining was
carried out with hematoxylin. Finally, the sections were immersed in
an ethanol and xylene bath and mounted for examination. 
Cell proliferation assay. SAS and HSC-2 cells were plated in a 96-
well plate at 5×103 cells per well in the presence of 1-500 nM
iMDK. An MTS assay was performed to obtain a relative cell
number after 24 hours of incubation under the experimental
conditions (CellTiter 96 AQueous One Solution Cell Proliferation
Assay; Promega, Madison, WI, USA).
Immunoblot analysis. SAS and HSC-2 cells after treatment with 20 nM
iMDK were rinsed once with ice-cold phosphate-buffered saline and
lysed in an ice-cold lysis buffer [50 mmol/l Tris-HCl (pH 7.4),
containing 150 mmol/l NaCl, 1% Triton X-100, 1% NP-40, 10 mmol/l
NaF, 100 mmol/l leupeptin, 2 mg/ml aprotinin, and 1 mmol/l
phenylmethyl sulfonyl fluoride]. Cell lysates containing 25 μg of total
protein in a lysis buffer were electrophoresed in 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gels, and the proteins were
transferred to polyvinylidene difluoride membranes (Immobilon-P;
Millipore, Bedford, MA, USA). Each membrane was incubated with
primary and secondary antibodies according to the ECL
chemiluminescence protocol (RPN2109; Amersham Biosciences,
Buckinghamshire, UK) to detect secondary antibody binding.
Antibodies against phospho-protein kinase B (pAKT) (Ser473) 1:2000
and phospho-p44/42 mitogen-activated protein kinase (MAPK)
(ERK1/2) (Thr202/Tyr204) 1:1000 were purchased from Cell Signaling
Technology (Danvers, MA, USA). Antibody to midkine (1:1000) was
purchased from Abcam; antibody to pleiotrophin [a member of a family
of structurally related to midkine (12)] (1:500) was purchased from
purchased from Abcam; and antibody to beta-actin (1:5000) was
purchased from Sigma Aldrich (St. Louis, MO, USA) and used at the
indicated dilution. HRP-conjugated goat anti-rabbit antibodies or goat
anti-mouse IgG were used as secondary antibodies at a 1:5000 dilution.
In vitro angiogenesis assay. Experiments on the angiogenesis using
HUVECs were conducted in 24-well dishes with an angiogenesis
kit (Kurabo, Osaka, Japan) according to the manufacturer’s
instructions. Briefly, HUVECs were cultured with or without
vascular endothelial growth factor (VEGF) and iMDK, and the
medium was changed every 3 days. After 11 days, HUVECs were
stained for CD31 with a Tubule Staining Kit (Kurabo). The luminal
area was evaluated with an Angiogenesis Image Analyzer (Kurabo)
in three different fields for each well and analyzed statistically.
Animal experiments. The experimental protocols were approved by
the Ethics Review Committee for Animal Experimentation of the
Okayama University Graduate School of Medicine and Dentistry
(Ethics Committee reference number: OKU-2015577). Human oral
squamous cell carcinoma xenografts were established in 5-week-
old female BALB/c nude mice (Clea Japan, Tokyo, Japan) by
subcutaneous inoculation of 1×106 SAS and HSC-2 cells into the
dorsal flank as described previously (17, 18). The mice were
randomly assigned into two groups. After 2 weeks, iMDK-treated
group of mice was intraperitoneally injected with 100 μl solution
containing iMDK (9 mg/kg/week) every day. The tumor volume
was measured from 14 days to 28 or 36 days after tumor
inoculation. The tumor volume (mm3) was calculated using the
equation 4π/3 × (r1/2 + r2/2)3, where r1=longitudinal radius, and
r2=transverse radius, as described previously (17, 18). All of the
mice were sacrificed on day 29 or 37 after tumor inoculation, and
tumors were removed and prepared for immunohistochemistry;
sections were sequentially deparaffinized through a series of
xylene, graded ethanol, and water immersion steps. After being
autoclaved in 0.2% citrate buffer for 15 minutes, the sections were
incubated with 3% hydrogen peroxide for 30 minutes to block
endogenous peroxidase activity. A primary antibody to midkine
(rabbit IgG), and anti-CD31 (rabbit IgG) from Abcam were used
for the immunohistochemical analysis. The specimens were
incubated with 1:200 (midkine) and 1:50 (CD31) dilutions of the
antibody overnight at 4˚C, followed by three washes with TBS. The
slides were then treated with a streptavidin-biotin complex,
EnVision HRP (Dako) for 60 minutes at a dilution of 1:100. The
immunoreaction was visualized using a DAB substrate-chromogen
solution (Dako Cytomation Liquid DAB Substrate Chromogen
System; Dako), and counterstaining was carried out with
hematoxylin. Finally, the sections were immersed in an ethanol and
xylene bath and mounted for examination. 
Apoptosis assay. Terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) staining was performed to detect
apoptosis using the DeadEnd colormetric TUNEL system (Promega)
according to the manufacturer’s protocol.
Statistical analysis. Data were analyzed using unpaired Student’s t-
test for the analysis of two groups, one-way ANOVA, post hoc
Bonferroni and Dunnett’s test for the analysis of multiple group
comparisons, and a log-rank test for Kaplan–Meier analysis using
SPSS statistical software (version 10; Chicago, IL, USA). Results
are expressed as means±SDs. A value of p<0.05 was considered to
indicate statistical significance.
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Figure 1. Expression of midkine (MDK) in mandibular oral squamous cell carcinoma and the effect of midkine inhibitor (iMDK) on oral
squamous cell carcinoma xenografts in mice. A: Immunohistochemical staining for MDK in a normal epithelium and mandibular oral squamous
cell carcinoma. The insets shown in the left panel are magnified in middle and right panels respectively. Scale bar=50 μm. B and C:
Macroscopic appearance, volume and immunohistochemical analysis of HSC-2 (B) and SAS (C) xenograft tumors in mice with after treatment
with iMDK. Left panel: Tumor volumes and images of xenograft tumors derived from HSC-2 and SAS cells, dissected from mice treated with
iMDK (scale bar=10 mm). The volumes of tumors derived from HSC-2 or SAS cells were reduced after treatment with iMDK (9 mg/kg) in a
xenograft mouse model. Dimethyl sulfoxide was used for the control group. Tumor growth is expressed as mean tumor volume; bars represent
the SDs. Statistically significantly different at *p<0.05 and **p<0.01. Right panel: Representative histology of MDK and CD31 expression in
xenograft tumors from mice treated with iMDK. Scale bar=50 μm.
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Figure 2. The effect of midkine inhibitor (iMDK) on oral squamous cell carcinoma cell growth and signaling and Human vascular endothelial cell
(HUVEC) tube formation. A: Growth-inhibitory effects of iMDK on HSC-2 and SAS cells. B: Detection of midkine (MDK), phospho-extracellular
signal-regulated kinase (pERK), phospho-protein kinase B (pAKT), pleiotrophin (PTN) in HSC-2 and SAS cells by immunoblotting after treatment
with 20 nM iMDK. C: Relative capillary length of CD31-positive HUVECs on type 1 collagen with or without 10 ng/ml VEGF in the presence of
the indicated amount of iMDK. *Statistically significantly different at p<0.05.
Results
Expression of midkine in oral squamous cell carcinoma.
Figure 1A illustrates a representative histologic pattern of
midkine in the human gingival epithelium. Midkine was not
detected in the normal gingival epithelium (Figure 1A,
middle panel). The expression of midkine was strongly
observed throughout the squamous cell carcinoma (Figure
1A, right panel). This result suggested that midkine might be
related to the proliferation and survival of oral squamous cell
carcinoma cells.
Administration of iMDK suppresses tumor growth in vivo. To
analyze the antitumor effect of iMDK in vivo, we established
an oral squamous cell carcinoma xenograft tumor derived from
HSC-2 and SAS cells in nude mice. The animals were treated
with an intraperitoneal administration of iMDK (9 mg/kg).
Administration five times a week started 14 days after tumor
inoculation for 14 days (HSC-2 cells) or 22 days (SAS cells),
and tumor volume was measured each day during the
treatment. As shown in Figure 1, both HSC-2 (Figure 1B) and
SAS (Figure 1C) xenograft volumes significantly decreased in
iMDK-treated mice compared with controls. No severe effects
occurred on day 14 (HSC-2 cells) or day 22 (SAS cells) during
the treatment. At sacrifice, after the treatment with iMDK, the
tumors were excised and examined histologically.
Immunohistochemical analysis showed a significant decrease
of midkine expression and a reduction in CD31-positive
endothelial cells in HSC-2 and SAS tumor sections from
iMDK-administered mice (Figure 1B and C, right panel).
These results suggested that iMDK might suppress tumor
growth by the regulation of angiogenesis. 
Inhibition of midkine by iMDK suppressed cell growth of
oral squamous cell carcinoma in vitro. An MTS assay was
performed to determine the iMDK inhibitory effect on cell
growth. As shown in Figure 2A, iMDK significantly reduced
the proliferation of both HSC-2 (10 nM) and SAS (20 nM)
cells, and the observed effects were dose-dependent (p<0.05,
Figure 2A). Next, in order to investigate which signaling
pathway is involved in iMDK reduction of cell proliferation,
we analyzed expression of midkine and of the molecules
downstream of midkine by immunoblot analysis. As shown
in Figure 2B, 20 nM iMDK inhibited midkine expression in
both HSC-2 and SAS cells, indicating that iMDK has
effective and specific action in midkine-positive oral
squamous cell carcinoma cells. Since the activation of ERK
MAPK and AKT is involved in tumorigenesis (19, 20), we
sought to determine whether ERK or AKT is suppressed by
iMDK. iMDK at 20 nM suppressed phosphorylation of ERK
from 30 minutes in both HSC-2 and SAS cells and the
suppression was continued for 12 h (Figure 2B). Moreover,
20 nM iMDK transiently up-regulated the phosphorylation
of AKT for 30 min in both HSC-2 and SAS cells and then
down-regulated it time-dependently compared to controls
(Figure 2B). However, 20 nM iMDK administration did not
change the expression of pleiotrophin. 
TUNEL staining was carried out to clarify whether the
inhibition of midkine induces apoptosis of human oral
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Figure 3. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) staining of HSC-2 cells and xenograft tumors treated
with 3-[2-(4-fluorobenzyl) imidazo [2,1-beta] thiazol-6-yl]-2H-chromen-2-
one (iMDK). A: TUNEL staining was performed after incubation of HSC-
2 cells with the indicated amount of iMDK. Scale bar=50 μm. B: TUNEL
staining of HSC-2 cell xenograft tumors from mice treated with dimethyl
sulfoxide (control) or iMDK was performed as described in the Materials
and Methods. Scale bar=200 μm. *Statistically significantly different at
p<0.05. 4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI).
squamous cell carcinoma cells. iMDK treatment at 10 and
100 nM significantly increased TUNEL-positive HSC-2 cells
within 48 hours compared to controls (p<0.05, Figure 3).
These results suggested that inhibition of midkine by iMDK
might inhibit proliferation and induce apoptosis through the
ERK and AKT pathway in human oral squamous cell
carcinoma cells.
iMDK suppressed endothelial cell tube formation. To clarify
whether iMDK suppresses angiogenesis, we determined its
inhibitory effect on normal HUVEC growth. In the presence
of 10 ng/ml VEGF, cells exhibited efficient tube formation
(Figure 2C). iMDK significantly inhibited the VEGF-
induced tube growth of HUVECs in a dose-dependent
fashion (p<0.05, Figure 2C).
Discussion
Previous studies revealed a role of midkine in oral squamous
cell carcinoma (14). Because midkine is known as a key
molecule for tumor cell proliferation (21), it is an ideal target
for treatment of oral squamous cell carcinoma. We found that
as lower gingival oral squamous cell carcinoma progressed,
the midkine immunostained area of increased. Our results
indicated that midkine expression can affect oral squamous
cell carcinoma development and progression; furthermore, it
might be a biomarker for cancer screening and predicting
outcome of oral squamous cell carcinoma. In this study, we
found that inhibition of midkine by iMDK might be a
promising approach for the treatment of oral squamous cell
carcinoma. Midkine was highly expressed in human oral
squamous cell carcinoma, and iMDK treatment displayed
significant inhibitory effects on the proliferation and
apoptosis of oral squamous cell carcinoma cells in vitro.
Midkine is known to activate not only the AKT pathway
but also the MAPK pathway in primary neuronal culture (22)
and myocardium (23). In our study, iMDK inhibited the ERK
and AKT pathways, and transiently activated AKT in both
HSC-2 and SAS cells. The mechanisms by which iMDK
inhibit the AKT pathway after transient activation are
unknown. The up-regulation of the AKT pathway might be a
compensation for down-regulation of the ERK pathway in
HSC-2 and SAS cells. Treatment of HSC-2 and SAS cells
with iMDK did not influence the expression of the
pleiotrophin, indicating that iMDK specifically inhibits
midkine signaling.
Angiogenesis creates a tumor microenvironment that
enhances tumor progression; endothelial cells, as the major
component making up blood vessels, proliferate much more
rapidly during angiogenesis than under normal conditions (24).
Administration of iMDK exhibited efficacy in the oral
squamous cell carcinoma xenograft model. Inhibition of tumor
growth was associated with clear down-regulation of midkine
expression and neovascularization in mice with oral squamous
cell carcinoma xenografts. Several studies have demonstrated
that midkine plays an important role in tumor angiogenesis (9).
It was also reported that midkine-binding peptides and novel
iMDK inhibitors inhibited tumor-associated angiogenesis in
hepatocarcinoma and lung cancer xenograft models in vivo (4).
In the present study, iMDK significantly inhibited capillary
formation in HUVECs induced by VEGF. These data
suggested that the inhibition of midkine by iMDK might
suppress angiogenesis and endothelial cell survival in human
oral squamous cell carcinoma.
In summary, this study is, to the best of our knowledge,
the first to show that midkine should be considered a target
for the treatment of oral squamous cell carcinoma. The
iMDK effect was mediated through down-regulation of the
midkine protein directly, which is involved in the survival
and angiogenesis of cancer cells. Although further studies are
needed, including identification of direct iMDK targets, and
safety validation, the use of iMDK alone or in combination
with other agents might be considered an attractive approach
to treating oral squamous cell carcinoma.
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